2-[4-(4-Methylphenyl)-1,3-thiazol-2-yl]pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-[4-(4-Methylphenyl)-1,3-thiazol-2-yl]pyridine
• 英文别名: 4-(4-methylphenyl)-2-pyridin-2-yl-1,3-thiazole
• 化学式: C₁₅H₁₂N₂S
• mdl: MFCD07269213
• 分子量: 252.3
• InChiKey: UEFFIKGPZCFIHD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS
  申请人：Baylor College Of Medicine

  公开号：EP2120580A2

  公开（公告）日：2009-11-25
• COMPOSITIONS OF FATOSTATIN BASED HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：FGH BIOTECH, INC.

  公开号：US20180000801A1

  公开（公告）日：2018-01-04

  The present invention relates to compounds, pharmaceutical compositions and formulations that have a structure (I). The compounds comprise a heterocyclic ring where W, X, Y, and Z generally and independently are S, N or C with the proviso that at least 2 of these positions in the ring are other than carbon. A pyridine or a substituted pyridine A ring and a phenyl or a substituted phenyl B ring are covalently bonded to the heterocyclic ring. Further provided are methods for treating a metabolic disorder, cell proliferative disease, reducing body weight or increasing thermogenesis during weight loss with the compounds of structure as described or pharmaceutically acceptable salt or stereoisomer thereof or both.
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT DE TROUBLES MÉTABOLIQUES
  申请人：BAYLOR COLLEGE MEDICINE

  公开号：WO2008097835A2

  公开（公告）日：2008-08-14

  [EN] The present invention relates to treatment and/or prevention of one or more metabolic disorders utilizing fatostatin A and/or a derivative and/or analog thereof. In other aspects, the compound for treatment and/or prevention of one or more metabolic disorders utilizes an A-B-C tripartite structure, wherein A, B, and C are identical or non-identical structures and are described in detail herein. In specific aspects, the metabolic disorder includes obesity or diabetes, for example.
  [FR] La présente invention concerne le traitement et/ou la prévention d'un ou plusieurs troubles métaboliques utilisant de la fatostatine A et/ou un dérivé et/ou un analogue de celle-ci. Dans d'autres aspects, le composé de traitement et/ou de prévention d'un ou plusieurs troubles métaboliques utilise une structure tripartite A-B-C, dans laquelle A, B et C sont des structures identiques ou non identiques et sont décrits en détail ici. Dans des aspects spécifiques, le trouble métabolique comprend l'obésité ou le diabète, par exemple.